Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007;3(5):699-702.

Effect of high-dose milnacipran in patients with depression

Masatoshi Hayashi  1 , Masaru Mimura, Tempei Otsubo, Kunitoshi Kamijima
Affiliations

Effect of high-dose milnacipran in patients with depression

Masatoshi Hayashi et al. Neuropsychiatr Dis Treat. 2007.

Abstract

To investigate the antidepressant effect of high-dose milnacipran, we retrospectively compared three groups of inpatients with major depression; those who were given milnacipran >100-150 mg/day (high-dose milnacipran group), those treated with milnacipran at maximum doses of 50-100 mg/day (standard-dose milnacipran group), and those treated with paroxetine at maximum doses of 40 mg/day (paroxetine group). The Hamilton Depression Rating Scale (HAM-D) scores of the three groups showed significant decrease at discharge compared to the scores at admission, indicating improvement of depressive symptoms for each group. However, the mean HAM-D score on admission was significantly lower for the standard-dose milnacipran group than the high-dose milnacipran and paroxetine groups. Additional intermediate assessment of the high-dose milnacipran group showed that the effect of milnacipran was dose-dependent with an additional improvement when patients were increase from 100 to 150 mg/day. These results suggest that patients suffering from moderate to severe depression with relative high HAM-D scores may benefit from treatment with high-dose milnacipran.

Keywords: dual-action antidepressant; high-dose; milnacipran; paroxetine; pharmacotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in HAM-D scores after milnacipran treatment at doses of up to 100 mg/day and 150 mg/day and paroxetine at a dose of 40 mg/day *** indicate a significant difference (p < 0.001) from admission.
Figure 2
Figure 2
Changes in HAM-D scores in patients for whom milnacipran was increased to 150 mg/day. *** indicate a significant difference (p < 0.001) between the values indicated.
See this image and copyright information in PMC

References

    1. Ansseau M, von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology. 1989;98:163–8. - PubMed
    1. Guelfi JD, Ansseau M, Corrubl EJ, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacology. 1998;13:121–8. - PubMed
    1. Kanemoto K, Matsubara M, Yamashita K, et al. Controlled comparison of two different doses of milnacipran in major depressive outpatients. Int Clin Psychopharmacol. 2004;19:343–6. - PubMed
    1. Morishita S. A clinical case of relapsed depression improved with high dose of milnacipran. Jpn J Psychiatry. 2003;8:257–60.
    1. Puozzo C, Filaquier C, Briley M. Plasma levels of F 2207, midalcipran, a novel antidepressant, after single oral administration in volunteers. Br J Clin Pharmacol. 1985;20:291.

LinkOut - more resources